|
| Press Releases |
|
 |
|
| Tuesday, June 12, 2018 |
|
|
Novotech Signs MOU with China Medical University Hospital in Taiwan to Offer Enhanced Services for Global Trials |
| Asia-Pacific specialist CRO Novotech announced today it has signed a Memorandum of Understanding (MOU) with the China Medical University Hospital (CMUH) in Taiwan to facilitate high-quality and rapid feasibility, start-up and recruitment processes. http://www.cmuh.cmu.edu.tw/ more info >> |
|
| Friday, May 18, 2018 |
|
|
Novotech says Federal Budget R&D Tax Support Keeps Australia Globally Competitive for Quality Clinical Trials |
| Leading Asia Pacific CRO Novotech commended the Turnbull Government's Federal Budget decision to exclude clinical trials activity from a A$4m cap on cash refunds, or any lifetime cap on refunds. more info >> |
|
| Friday, June 23, 2017 |
|
|
Novotech signs Central Lab Services Agreement with Sonic Clinical Trials |
| Asia Pacific specialist CRO Novotech announced today it has expanded its business offering to include central lab services through a preferred partnership agreement with Sonic Clinical Trials, an affiliate of international healthcare company, Sonic Healthcare. more info >> |
|
| Tuesday, April 18, 2017 |
|
|
Novotech signs MOU with South Korea's leading medical center, the Asan Medical Center |
| Asia Pacific specialist CRO Novotech announced today it has signed a Memorandum of Understanding (MOU) with South Korea's largest medical institution - The Asan Medical Center's (AMC) Clinical Trial Center. The MOU formalises Novotech's relationship with the internationally-leading medical center and its principal investigators. more info >> |
|
| Thursday, March 9, 2017 |
|
|
New Research reveals Asia poised as Preferred Destination for Clinical Trials |
| Frost & Sullivan released a white paper, 'Asia: Preferred Destination for Clinical Trials', with Asia Pacific CRO Novotech presenting the findings to an audience of senior biotechnology and pharmaceutical executives in a private event at the Outsourcing in Clinical Trials - West Coast (OCT-WC 2017) conference, held Feb 22-23 in Burlingame, Ca. (USA). more info >> |
|
| Friday, March 3, 2017 |
|
|
New Frost & Sullivan research reveals Asia as Preferred Destination for Clinical Trials |
| Frost & Sullivan released its latest white paper, 'Asia: Preferred Destination for Clinical Trials', with Asia Pacific specialist CRO Novotech. Research from the new white paper revealed Asia is quickly becoming a clinical research powerhouse. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
Wintermar Offshore (WINS:JK) Reports 1H2025 Results
Jul 30, 2025 19:56 HKT/SGT
|
|
|
Hong Kong Shopping Festival Returns in August with Bigger and Better 2nd Edition
Jul 30, 2025 18:29 HKT/SGT
|
|
|
Production, Sales and Export Results for June, 2025
Jul 30, 2025 18:24 JST
|
|
|
Sales, Production, and Export Results for the First Half of 2025
Jul 30, 2025 18:06 JST
|
|
|
Introducing the Meshy 5 Preview: Smarter AI, Cleaner Models, Bigger Animation Potential 
Jul 30, 2025 17:00 JST
|
|
|
Ongoing Share Buybacks Demonstrate Confidence, Shoucheng Holdings Boosts Market Expectations with Concrete Action
Jul 30, 2025 11:00 HKT/SGT
|
|
|
Collaborative Development of Ultra-Compact and Lightweight Satellite Communication User Terminals for Mobility with Mitsubishi Chemical, NICT, and TECHLAB
Jul 30, 2025 11:00 JST
|
|
|
Naoris Protocol Announces Upcoming TGE for $NAORIS
Jul 29, 2025 23:59 HKT/SGT
|
|
|
GEN and Sulfateq BV Announce Positive Phase 1 Trial Data on Investigational Drug SUL-238 for Alzheimer's and Other Neurodegenerative Diseases
Jul 29, 2025 23:13 HKT/SGT
|
|
|
Mitsubishi Heavy Industries Concludes Agreement with Modius to Provide DCIM Solutions for Data Centers Worldwide
Jul 29, 2025 20:00 JST
|
|
|
Biolog Enters the European Diagnostic Market, Bringing 45 Years of Anaerobic Culture Excellence
Jul 29, 2025 16:00 HKT/SGT
|
|
|
Set at the Osaka-Kansai Expo venue! Detailed program announced for the "OSAKA JAPAN SDGs Forum"
Jul 29, 2025 14:30 JST
|
|
|
GTJAI Achieved 'Carbon Neutrality' at Operational Level for the Third Consecutive Year
Jul 29, 2025 13:15 HKT/SGT
|
|
|
Unitree Races Toward IPO as Robot Applications Accelerate: Shoucheng Holdings Unlocks Dual-Engine Gains
Jul 29, 2025 11:30 HKT/SGT
|
|
|
LENVIMA(R) (lenvatinib) in Combination with Pembrolizumab and Transarterial Chemoembolization (TACE) Approved in China for the Treatment of Unresectable, Non-Metastatic Hepatocellular Carcinoma
Jul 29, 2025 9:01 JST
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
